Lancet Respir Med

Tezepelumab cuts oral steroid dependence in severe asthma

December 4, 2025

In the phase 3b WAYFINDER trial (NCT05274815), 298 adults with severe, oral corticosteroid (OCS)-dependent asthma received tezepelumab 210 mg SC every 4 weeks for 52 weeks, following a 4-week stable baseline dosing. By week 52, ~90% reduced their prednisone to ≤5 mg/day, and 50.3% fully discontinued OCS without loss of asthma control. Benefits were consistent across pre-specified subgroups based on baseline eosinophil count, fractional exhaled nitric oxide level, and allergy status. Serious adverse events occurred in 9.4%, with 1.3% discontinuing treatment.

Source:

Jackson DJ, et al. (2025, November 26). Lancet Respir Med. Oral corticosteroid reduction and discontinuation in adults with corticosteroid-dependent, severe, uncontrolled asthma treated with tezepelumab (WAYFINDER): a multicentre, single-arm, phase 3b trial. https://pubmed.ncbi.nlm.nih.gov/41317738/